Grifols, S.A. (GRFS) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - General industry. The company is headquartered in Barcelona, Spain. The current CEO is Jose Ignacio Abia Buenache.
GRFS has IPO date of 2011-06-02, 23,833 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $7.19B.
Grifols, S.A. is a Barcelona-based biopharmaceutical company founded in 1940 that specializes in the procurement, manufacture, and distribution of plasma-derived therapeutic products and diagnostic solutions. Operating through five primary divisions—Bioscience, Hospital, Diagnostic, Bio Supplies, and Others—the company develops innovative treatments for chronic, rare, and life-threatening diseases, including immunoglobulins, clotting factors, and albumin. Grifols serves a broad customer base spanning hospitals, blood banks, healthcare systems, and diagnostic laboratories worldwide, providing comprehensive solutions for conditions such as hemophilia, immune deficiencies, and infectious diseases. The company maintains a technology collaboration with Mondragon and distributes its products through hospitals, wholesalers, distributors, and national health systems globally.
